These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
27. Blastocystis subtypes isolated from irritable bowel syndrome patients and co-infection with Helicobacter pylori. El-Badry AA; Abd El Wahab WM; Hamdy DA; Aboud A Parasitol Res; 2018 Jan; 117(1):127-137. PubMed ID: 29138961 [TBL] [Abstract][Full Text] [Related]
28. [Role of Dientamoeba fragilis and Blastocystis spp. in Irritable Bowel Syndrome]. Mumcuoğlu I; Coşkun FA; Aksu N; Pürnak T; Güngör C Turkiye Parazitol Derg; 2013; 37(2):73-7. PubMed ID: 23955902 [TBL] [Abstract][Full Text] [Related]
29. Immunomodulation of enteric neural function in irritable bowel syndrome. O'Malley D World J Gastroenterol; 2015 Jun; 21(24):7362-6. PubMed ID: 26139983 [TBL] [Abstract][Full Text] [Related]
30. Fecal microbiota transplantation for managing irritable bowel syndrome. El-Salhy M; Mazzawi T Expert Rev Gastroenterol Hepatol; 2018 May; 12(5):439-445. PubMed ID: 29493330 [TBL] [Abstract][Full Text] [Related]
31. The gut microbiome and irritable bowel syndrome: State of art review. Salem AE; Singh R; Ayoub YK; Khairy AM; Mullin GE Arab J Gastroenterol; 2018 Sep; 19(3):136-141. PubMed ID: 29935865 [TBL] [Abstract][Full Text] [Related]
32. Investigation of Dientamoeba fragilis and Blastocystis in patients from Turkey with ulcerative colitis and irritable bowel syndrome: Any relation with genotypes? Unalan-Altintop T; Vahabov C; Ergunay K; Kurt O; Kav T; Akyon Y; Erguven S Acta Trop; 2022 Jul; 231():106451. PubMed ID: 35390312 [TBL] [Abstract][Full Text] [Related]
33. Biomarkers as a diagnostic tool for irritable bowel syndrome: where are we? Camilleri M; Halawi H; Oduyebo I Expert Rev Gastroenterol Hepatol; 2017 Apr; 11(4):303-316. PubMed ID: 28128666 [TBL] [Abstract][Full Text] [Related]
34. Review article: evidence for the role of gut microbiota in irritable bowel syndrome and its potential influence on therapeutic targets. Dupont HL Aliment Pharmacol Ther; 2014 May; 39(10):1033-42. PubMed ID: 24665829 [TBL] [Abstract][Full Text] [Related]
35. Pathogenic factors involved in the development of irritable bowel syndrome: focus on a microbial role. Bolino CM; Bercik P Infect Dis Clin North Am; 2010 Dec; 24(4):961-75, ix. PubMed ID: 20937460 [TBL] [Abstract][Full Text] [Related]
36. Parasitic infections in irritable bowel syndrome patients: evidence to propose a possible link, based on a case-control study in the south of Iran. Shafiei Z; Esfandiari F; Sarkari B; Rezaei Z; Fatahi MR; Hosseini Asl SMK BMC Res Notes; 2020 Jun; 13(1):264. PubMed ID: 32487206 [TBL] [Abstract][Full Text] [Related]
37. Irritable bowel syndrome: a review of the general aspects and the potential role of vitamin D. Barbalho SM; Goulart RA; Araújo AC; Guiguer ÉL; Bechara MD Expert Rev Gastroenterol Hepatol; 2019 Apr; 13(4):345-359. PubMed ID: 30791775 [TBL] [Abstract][Full Text] [Related]
38. Irritable bowel syndrome: a microbiome-gut-brain axis disorder? Kennedy PJ; Cryan JF; Dinan TG; Clarke G World J Gastroenterol; 2014 Oct; 20(39):14105-25. PubMed ID: 25339800 [TBL] [Abstract][Full Text] [Related]
39. Treatment of irritable bowel syndrome with probiotics. An etiopathogenic approach at last? Bixquert Jiménez M Rev Esp Enferm Dig; 2009 Aug; 101(8):553-64. PubMed ID: 19785495 [TBL] [Abstract][Full Text] [Related]
40. Irritable bowel syndrome in Egyptian patients: plausible risk factors and association with intestinal protozoa. Salem AI; El-Taweel HA; Madkour MA; Abd El-Latif NF; Abd-Elrazeq ES Trop Doct; 2019 Jul; 49(3):184-188. PubMed ID: 30885054 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]